Fenofibrate increases the L-arginine: ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration

Atherosclerosis

Volumn 173, Issue 2, 2004, Pages 239-244

  Dierkes, Jutta ^a   Westphal, Sabine ^a   Martens Lobenhoffer, Jens ^a   Luley, Claus ^a   Bode Böger, Stefanie M ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

ADMA; Asymmetrical dimethylarginine; DDAH; Dimethylarginine dimethylaminohydrolse; GFR; Glomerular filtration rate; HDL C; High density lipoprotein cholesterol; LDL C; tHcy; Total homocysteine (sum of free and protein bound homocysteine)

Indexed keywords

ALLOPURINOL; ANTILIPEMIC AGENT; ARGININE; CHOLESTEROL; CYANOCOBALAMIN; FENOFIBRATE; FOLIC ACID; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; METOPROLOL; N(G),N(G) DIMETHYLARGININE; PLACEBO; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GOUT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; ARGININE; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROBABILITY; PROCETOFEN; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1842737023     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.12.004     Document Type: Article

References (36)

1. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. 22:2002;2032-2037.
2. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S.et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146.
3. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43:1999;542-548.
4. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20:2000;1557-1564.
5. Boger R.H., Lentz S.R., Bode-Boger S.M., Knapp H.R., Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin. Sci. Lond. 100:2001;161-167.
6. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 104:2001;2569-2575.
7. Valkonen V.P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso J.et al. Risk of acute coronary events and serum concentration of asymmetrical imethylarginine. Lancet. 358:2001;2127-2128.
8. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L.et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 358:2001;2113-2117.
9. Yoo J.H., Lee S.C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 158:2001;425-430.
10. Bode-Böger S.M., Böger R.H., Kienke S.et al. Elevated L-arginine /dimethylarginine ratio may be a better index for the relative substrate availability of the NO-synthase as the L-arginine or ADMA concentration alone. BBRC. 219:1996;598-603.
11. Boger R.H., Bode-Boger S.M., Thiele W., Creutzig A., Alexander K., Frolich J.C. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32:1998;1336-1344.
12. Gotto A.M. Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 144(Suppl):2002;S33-S42.
13. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 341:1999;498-511.
14. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:1990;645-650.
15. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
16. Dierkes J., Westphal S., Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 354:1999;219-220.
17. de Lorgeril M., Salen P., Paillard F.et al. Lipid-lowering drugs and homocysteine. Lancet. 353:1999;209-210.
18. Jonkers I.J.A.M., de Man F.H.A.F., Onkenhout W.et al. Implication for fibrate therapy for homocysteine. Lancet. 354:1999;1208.
19. Dierkes J., Westphal S., Kunstmann S., Banditt P., Lossner A., Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis. 158:2001;161-164.
20. Stulc T., Melenovsky V., Grauova B., Kozich V., Ceska R. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition. 17:2001;721-723.
21. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J. Am. Coll. Cardiol. 38:2001;111-116.
22. Capell W.H., DeSouza C.A., Poirier P., Bell M.L., Stauffer B.L., Weil K.M.et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 23:2003;307-313.
23. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
24. Martens-Lobenhoffer J., Bode-Böger S.M. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J. Chromatogr. B. Biomed. Sci. Appl. 798(2):2003;231-239.
25. Lindner W., Wainer I.W. Requirements for initial assay validation and publication in J. Chromatography B. J. Chromatogr. B: Biomed. Sci. Appl. 707:1998;1-2.
26. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J. Chromatogr. B: Biomed. Sci. Appl. 689:1997;175-180.
27. Vester B., Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur. J. Clin. Chem. Clin. Biochem. 29:1991;549-554.
28. Meade T., Zuhrie R., Cook C., Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 325:2002;1139.
29. Hottelart C., el Esper N., Achard J.M., Pruna A., Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Article in French Nephrologie. 20:1999;41-44.
30. Hottelart C., El Esper N., Rose F., Achard J.M., Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 92:2002;536-541.
31. Wu G., Morris S.M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336:1998;1-17.
32. Paiva H., Laakso J., Lehtimaki T., Isomustajarvi M., Ruokonen I., Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 41:2003;219-222.
33. Nijveldt R.J., Van Leeuwen P.A., Van Guldener C., Stehouwer C.D., Rauwerda J.A., Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol. Dial Transplant. 17:2002;1999-2002.
34. Paiva H., Lehtimaki T., Laakso J., Ruokonen I., Rantalaiho V., Wirta O. et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism. 52:2003;303-307.
35. Mann J.F., Gerstein H.C., Dulau-Florea I., Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int. Suppl. 84:2003;192-196.
36. Sydow K., Schwedhelm E., Arakawa N. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc. Res. 57:2003;244-252.